

Juan F Navarro-Gonzlez

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4796805/juan-f-navarro-gonzalez-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163 papers	6,339 citations	42 h-index	76 g-index
196 ext. papers	7,479 ext. citations	4.9 avg, IF	5.88 L-index

#	Paper	IF	Citations
163	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology.. <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 865-872	4.5	1
162	Klotho expression in peripheral blood circulating cells is associated with vascular and systemic inflammation in atherosclerotic vascular disease.. <i>Scientific Reports</i> , 2022 , 12, 8422	4.9	1
161	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021 , 41, 391-402	0.4	
160	Kv1.3 Channel Inhibition Limits Uremia-Induced Calcification in Mouse and Human Vascular Smooth Muscle.. <i>Function</i> , 2021 , 2, zqaa036	6.1	1
159	Increased SGK1 activity potentiates mineralocorticoid/NaCl-induced kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 320, F628-F643	4.3	5
158	[Interleukin-17A: Possible mediator and therapeutic target in hypertension]. <i>Nefrologia</i> , 2021 , 41, 244-257	5.4	2
157	Interleukin-17A: Potential mediator and therapeutic target in hypertension. <i>Nefrologia</i> , 2021 , 41, 244-257	5.4	1
156	Osteoporosis in chronic kidney disease: A essential challenge. <i>Medicina Clínica</i> , 2021 , 158, 27-27	1	1
155	Bases para la creación de las unidades clínicas cardiorrenales. Documento de consenso de los grupos de trabajo cardiorrenal de la SEC y la SEN. <i>REC: CardioClinics</i> , 2021 , 56, 284-284	0.2	3
154	817-P: Inside CKD: Modeling the Direct Economic Burden of Concomitant Chronic Kidney Disease and Type 2 Diabetes. <i>Diabetes</i> , 2021 , 70, 817-P	0.9	
153	Pathophysiological Implications of Imbalances in Fibroblast Growth Factor 23 in the Development of Diabetes. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
152	Urinary Dickkopf-3: a new biomarker for CKD progression and mortality. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 2199-2207	4.3	0
151	Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics. <i>Nutrients</i> , 2021 , 13,	6.7	1
150	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021 , 41, 391-402	1.5	1
149	Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia. <i>Rheumatology</i> , 2021 , 60, 371-379	3.9	8
148	Extracellular water/total body water ratio as predictor of mortality in hemodialysis patients. <i>Renal Failure</i> , 2021 , 43, 821-829	2.9	1
147	Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 681-687	4.5	2

146	Klotho as a biomarker of subclinical atherosclerosis in patients with moderate to severe chronic kidney disease. <i>Scientific Reports</i> , 2021 , 11, 15877	4.9	2
145	Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3-5 Not on Dialysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
144	Inflammatory Targets in Diabetic Nephropathy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	46
143	Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
142	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, i13-i23	4.3	13
141	Association between serum levels of Klotho and inflammatory cytokines in cardiovascular disease: a case-control study. <i>Aging</i> , 2020 , 12, 1952-1964	5.6	11
140	New information on phosphate binder interactions with vitamin K. <i>Nefrologia</i> , 2020 , 40, 369-370	0.4	
139	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	27
138	Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications. <i>Frontiers in Medicine</i> , 2020 , 7, 628289	4.9	8
137	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 313-321	4.5	22
136	Will the new hypoglycaemic agents be effective on renal and cardiovascular protection in diabetes and renal diabetic disease?. <i>Nefrologia</i> , 2019 , 39, 3-10	0.4	1
135	A Novel Heterozygous Deletion Variant in Gene Leading to Haploinsufficiency and Impairment of Fibroblast Growth Factor 23 Signaling Pathway. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	1
134	Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	25
133	FGF23 and Klotho Levels are Independently Associated with Diabetic Foot Syndrome in Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	5
132	Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 2079-2088	4.3	4
131	Fibroblast growth factor 23 expression in human calcified vascular tissues. <i>Aging</i> , 2019 , 11, 7899-7913	5.6	8
130	Inflammation in Diabetic Kidney Disease. <i>Nephron</i> , 2019 , 143, 12-16	3.3	65
129	Phenotypic Modulation of Cultured Primary Human Aortic Vascular Smooth Muscle Cells by Uremic Serum. <i>Frontiers in Physiology</i> , 2018 , 9, 89	4.6	14

128	Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. <i>Diabetes Care</i> , 2018 , 41, 1817-1820	14.6	36
127	FP389DOES VELPHORO (SUCROFERRIC OXYHYDROXIDE) RESOLVE THE PROBLEM OF NON-ADHERENCE TO PHOSPHATE BINDERS IN HEMODIALYSIS? :STRATEGIES OF USE. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i165-i165	4.3	
126	Mineralocorticoid Receptor Mediates Uremic Serum-Induced Increase in Endothelial Cell Dysfunction. <i>FASEB Journal</i> , 2018 , 32, 904.8	0.9	
125	FP612PROSPECTIVE REAL-WORLD DATA WITH SUCROFERRIC OXYHYDROXIDE IN HEMODIALYSIS PATIENTS: EFFECTS ON MINERAL, IRON AND INFLAMMATORY PROFILE. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i248-i248	4.3	
124	Pharmacological interactions of phosphate binders. <i>Nefrologia</i> , 2018 , 38, 573-578	0.4	5
123	Anti-inflammatory profile of paricalcitol in kidney transplant recipients. <i>Nefrologia</i> , 2017 , 37, 622-629	1.5	2
122	SP812VITAMIN D RECEPTOR ACTIVATION REDUCES KLOTHO PROMOTER METHYLATION. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, iii416-iii416	4.3	
121	Soluble levels and endogenous vascular gene expression of are related to inflammation in human atherosclerotic disease. <i>Clinical Science</i> , 2017 , 131, 2601-2609	6.5	23
120	Cytokines in Diabetes and Diabetic Complications 2017 , 119-128		4
119	Anti-inflammatory profile of paricalcitol in kidney transplant recipients. <i>Nefrologia</i> , 2017 , 37, 622-629	0.4	1
118	ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?. <i>Nefrologia</i> , 2017 , 37, 567-571	0.4	5
117	Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 513-520	4.3	22
116	Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients. <i>Transplantation</i> , 2016 , 100, 2432-2438	1.8	10
115	Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. <i>Cytokine and Growth Factor Reviews</i> , 2016 , 28, 71-7	17.9	19
114	Dietary Quality and Adherence to Dietary Recommendations in Patients Undergoing Hemodialysis. <i>Journal of Renal Nutrition</i> , 2016 , 26, 190-5	3	48
113	What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?. <i>World Journal of Nephrology</i> , 2016 , 5, 471-81	3.6	17
112	Urinary Clara Cell Protein in Kidney Transplant Patients: A Preliminary Study. <i>Transplantation Proceedings</i> , 2016 , 48, 2884-2887	1.1	2
111	Vitamin D and Inflammation in Chronic Kidney Disease 2016 , 305-319		

110	Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease. <i>Journal of Cellular and Molecular Medicine</i> , 2016 , 20, 128-33	5.6	28
109	Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 1176-83	4.3	66
108	Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease. <i>Atherosclerosis</i> , 2015 , 242, 37-44	3.1	19
107	Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 220-9	12.7	351
106	Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. <i>Journal of Clinical Medicine</i> , 2015 , 4, 1325-47	5.1	44
105	The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years. <i>Journal of Clinical Medicine</i> , 2015 , 4, 1207-16	5.1	73
104	Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?. <i>Journal of Clinical Medicine</i> , 2015 , 4, 1866-89	5.1	13
103	Inflammatory cytokines in diabetic nephropathy. <i>Journal of Diabetes Research</i> , 2015 , 2015, 948417	3.9	149
102	Klotho in cardiovascular disease: Current and future perspectives. <i>World Journal of Biological Chemistry</i> , 2015 , 6, 351-7	3.8	15
101	Vascular calcification in patients with nondialysis CKD over 3 years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 654-66	6.9	93
100	The role of Mineralocorticoid Receptor on Human Aortic Endothelial Ion Channel Expression Profile in Chronic Kidney Disease. <i>FASEB Journal</i> , 2015 , 29, 844.19	0.9	
99	Reduced Klotho is associated with the presence and severity of coronary artery disease. <i>Heart</i> , 2014 , 100, 34-40	5.1	101
98	Pathophysiological implications of fibroblast growth factor-23 and Klotho and their potential role as clinical biomarkers. <i>Clinical Chemistry</i> , 2014 , 60, 933-40	5.5	15
97	Diabetic kidney disease: from physiology to therapeutics. <i>Journal of Physiology</i> , 2014 , 592, 3997-4012	3.9	86
96	Inflammation in diabetic kidney disease. <i>World Journal of Diabetes</i> , 2014 , 5, 431-43	4.7	73
95	Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. <i>Mediators of Inflammation</i> , 2014 , 2014, 670475	4.3	17
94	Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 282-4	4.3	81
93	Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4180-4	5.9	11

92	Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease. <i>Current Drug Targets</i> , 2014 , 15, 703-9	3	6
91	Implications of Klotho in vascular health and disease. <i>World Journal of Cardiology</i> , 2014 , 6, 1262-9	2.1	36
90	Expression of FGF23/KLOTHO system in human vascular tissue. <i>International Journal of Cardiology</i> , 2013 , 165, 179-83	3.2	71
89	Lanthanum Carbonate Modulates Inflammatory Profile in Hemodialysis Patients: Relationship with Fibroblast Growth Factor-23. <i>European Journal of Inflammation</i> , 2013 , 11, 75-86	0.3	1
88	Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 421-6	2.9	22
87	Relationship between inflammation and microalbuminuria in prehypertension. <i>Journal of Human Hypertension</i> , 2013 , 27, 119-25	2.6	16
86	ENaC modulators and renal disease. <i>Current Molecular Pharmacology</i> , 2013 , 6, 35-43	3.7	10
85	Activation of vitamin D receptors in the optimization of hyperparathyroidism secondary to dialysis. <i>Nefrologia</i> , 2013 , 33, 571-84	1.5	
84	FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. <i>Cytokine and Growth Factor Reviews</i> , 2012 , 23, 37-46	17.9	30
83	Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study. <i>BMC Nephrology</i> , 2012 , 13, 60	2.7	7
82	Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. <i>World Journal of Diabetes</i> , 2012 , 3, 7-18	4.7	76
81	Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 302, F647-57	4.3	120
80	Identification of permissive insertion sites for generating functional fluorescent mineralocorticoid receptors. <i>Endocrinology</i> , 2012 , 153, 3517-25	4.8	9
79	Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2011 , 7, 327-40	14.9	644
78	Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. <i>Journal of Diabetes and Its Complications</i> , 2011 , 25, 314-9	3.2	38
77	Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. <i>BMC Nephrology</i> , 2011 , 12, 53	2.7	54
76	Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 2272-9	6.9	69
75	Inflammatory pathways. <i>Contributions To Nephrology</i> , 2011 , 170, 113-123	1.6	13

74	Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 1004-10	10.2	59
73	Serum and gene expression profile of tumor necrosis factor-alpha and interleukin-6 in hypertensive diabetic patients: effect of amlodipine administration. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 51-9	3	20
72	Erdheim-Chester disease as cause of end-stage renal failure: a case report and review of the literature. <i>International Urology and Nephrology</i> , 2010 , 42, 1107-12	2.3	15
71	Infectious spondylodiscitis in hemodialysis. <i>Seminars in Dialysis</i> , 2010 , 23, 619-26	2.5	10
70	Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 1646-54	6.9	63
69	Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. <i>Seminars in Dialysis</i> , 2009 , 22, 37-44	2.5	98
68	Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. <i>Cytokine and Growth Factor Reviews</i> , 2009 , 20, 165-73	17.9	60
67	Best blood sample draw site during liver transplantation. <i>Transplantation Proceedings</i> , 2009 , 41, 991-3	1.1	5
66	Pathogenic perspectives for the role of inflammation in diabetic nephropathy. <i>Clinical Science</i> , 2009 , 116, 479-92	6.5	140
65	The role of inflammatory cytokines in diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 433-42	12.7	623
64	Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. <i>Journal of Hypertension</i> , 2008 , 26, 2168-75	1.9	34
63	Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 919-26	4.3	48
62	Hypercalciuria in pediatric patients with ureteropelvic junction obstruction is of genetic origin. <i>Scandinavian Journal of Urology and Nephrology</i> , 2007 , 41, 144-8		9
61	Magnesium in Chronic Renal Failure 2007 , 303-315		4
60	Inflammation and diabetic nephropathy. <i>Current Diabetes Reports</i> , 2006 , 6, 463-8	5.6	144
59	Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 3428-34	4.3	101
58	Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. <i>American Journal of Nephrology</i> , 2006 , 26, 562-70	4.6	169
57	The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. <i>Cytokine and Growth Factor Reviews</i> , 2006 , 17, 441-50	17.9	140

56	Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. <i>Scientific World Journal, The</i> , 2006 , 6, 908-17	2.2	79
55	Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. <i>Kidney International</i> , 2005 , S98-102	9.9	83
54	The role of inflammation as a pathogenic factor in the development of renal disease in diabetes. <i>Current Diabetes Reports</i> , 2005 , 5, 399-401	5.6	36
53	Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 2119-26	12.7	104
52	Inflammation and pathogenesis of diabetic nephropathy. <i>Metabolism: Clinical and Experimental</i> , 2004 , 53, 265-6; author reply 266-7	12.7	31
51	Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. <i>American Journal of Kidney Diseases</i> , 2003 , 42, 53-61	7.4	181
50	Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. <i>American Journal of Kidney Diseases</i> , 2003 , 42, 264-70	7.4	52
49	Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. <i>American Journal of Medicine</i> , 2003 , 114, 62-4	2.4	23
48	Effect of proinflammatory cytokines (IL-6, TNF-alpha, IL-1beta) on hemodynamic performance during orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2003 , 35, 1884-7	1.1	37
47	Association between anatomopathologic graft disorders during reperfusion and vena cava sIL-2r in orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2003 , 35, 1880-3	1.1	1
46	Randomized prospective comparison between erythropoietin and androgens in CAPD patients. <i>Kidney International</i> , 2002 , 61, 1537-44	9.9	50
45	Intradialytic amino acid supplementation. <i>Nephron</i> , 2002 , 90, 509	3.3	
44	Androgen therapy for anemia in elderly uremic patients. <i>International Urology and Nephrology</i> , 2001 , 32, 549-57	2.3	9
43	Low-density lipoprotein apheresis in homozygous familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 2001 , 88, 202-3	3	4
42	Renal failure, anaemia, cytokines and inflammation. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 1524-3	4.3	2
41	First experience in Spain with MARS in three patients with advanced liver failure. <i>Zeitschrift Fur Gastroenterologie</i> , 2001 , 39 Suppl 2, 20-1	1.6	1
40	Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin. <i>Transplantation</i> , 2001 , 72, 551	1.8	10
39	Serum magnesium and parathyroid hormone levels in dialysis patients. <i>Kidney International</i> , 2000 , 57, 2654	9.9	9

38	Amino acid losses during hemodialysis with polyacrylonitrile membranes: effect of intradialytic amino acid supplementation on plasma amino acid concentrations and nutritional variables in nondiabetic patients. <i>American Journal of Clinical Nutrition</i> , 2000 , 71, 765-73	7	54
37	Negative effect of angiotensin-converting enzyme inhibitors on erythropoietin response in CAPD patients. <i>American Journal of Nephrology</i> , 2000 , 20, 248	4.6	5
36	Cerivastatin-induced rhabdomyolysis. <i>Annals of Internal Medicine</i> , 2000 , 132, 598	8	21
35	Autosomal dominant polycystic kidney disease associated with familial sensorineural deafness. <i>Scandinavian Journal of Urology and Nephrology</i> , 1999 , 33, 63-5		1
34	Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. <i>Scandinavian Journal of Urology and Nephrology</i> , 1999 , 33, 121-5		24
33	Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 1999 , 34, 43-8	7.4	80
32	Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. <i>American Journal of Kidney Diseases</i> , 1999 , 33, 458-63	7.4	119
31	Effect of different membranes on amino-acid losses during haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 1998 , 13, 113-7	4.3	16
30	Control of severe proteinuria with losartan after renal transplantation. <i>American Journal of Nephrology</i> , 1998 , 18, 261-2	4.6	9
29	Bone loss in children with idiopathic hypercalciuria. <i>Nephron</i> , 1998 , 78, 341-2	3.3	11
28	Intradialytic cardiovascular stability with low calcium dialysate levels. <i>Nephron</i> , 1998 , 78, 120	3.3	
27	Effect of angiotensin-converting enzyme inhibitors on hematological parameters and recombinant human erythropoietin doses in peritoneal dialysis patients. <i>Nephron</i> , 1998 , 80, 239	3.3	4
26	Relationship between serum parathyroid hormone levels and lipid profile in hemodialysis patients. Evolution of lipid parameters after parathyroidectomy. <i>Clinical Nephrology</i> , 1998 , 49, 303-7	2.1	3
25	Androgens for the treatment of anemia in peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 1998 , 14, 232-5		7
24	Serum magnesium concentration and PTH levels. Is long-term chronic hypermagnesemia a risk factor for adynamic bone disease?. <i>Scandinavian Journal of Urology and Nephrology</i> , 1997 , 31, 275-80		31
23	Herpes simplex virus as a sentinel lesion for cytomegalovirus infection. <i>Nephrology Dialysis Transplantation</i> , 1997 , 12, 853	4.3	
22	Recurrent severe acute hepatitis and omeprazole. <i>Annals of Internal Medicine</i> , 1997 , 127, 1135-6	8	11
21	Idiopathic acute interstitial nephritis and uveitis associated with deafness. <i>Nephrology Dialysis Transplantation</i> , 1997 , 12, 781-4	4.3	6

20	Standards for ultrasound guidance of suprapubic bladder aspiration. <i>Pediatric Nephrology</i> , 1997 , 11, 607-92	26
19	Hemodialysis urea rebound and membrane biocompatibility: accuracy of Kt/V estimations. <i>Artificial Organs</i> , 1997 , 21, 91-5	2.6 2
18	Errors in the selection of dialysate concentrates cause severe metabolic acidosis during bicarbonate hemodialysis. <i>Artificial Organs</i> , 1997 , 21, 966-8	2.6 6
17	Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 1997 , 13, 257-9	7
16	Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 431-4	7.4 44
15	Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. <i>American Journal of Nephrology</i> , 1996 , 16, 268-72	4.6 25
14	Hiatal hernia in predialysis patients. <i>Nephrology Dialysis Transplantation</i> , 1996 , 11, 2370	4.3
13	Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. <i>American Journal of Nephrology</i> , 1996 , 16, 95-7	4.6 72
12	Acute cardiovascular effects of intravenous cyclosporine. <i>International Urology and Nephrology</i> , 1996 , 28, 575-81	2.3 4
11	Chinese herbs can themselves be harmful: comment on the article by Gertner et al. <i>Arthritis and Rheumatism</i> , 1996 , 39, 354-5	1
10	Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. <i>Metabolism: Clinical and Experimental</i> , 1995 , 44, 929-33	12.7 28
9	Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route. <i>Scandinavian Journal of Urology and Nephrology</i> , 1995 , 29, 11-4	16
8	Hepatitis B vaccine, hepatitis C virus infection, and haemodialysis. <i>Lancet, The</i> , 1995 , 346, 845	4.0 1
7	Diuretics, ACE inhibitors, and cardiac failure. <i>Lancet, The</i> , 1995 , 346, 700-1	4.0
6	Long-term hospital support for dialysis. <i>Lancet, The</i> , 1995 , 346, 902	4.0
5	Renal lymphoma and human immunodeficiency virus infection. <i>Mayo Clinic Proceedings</i> , 1995 , 70, 1224-56.4	
4	Influence of body iron stores on the serum erythropoietin concentration in hemodialyzed patients. <i>American Journal of Nephrology</i> , 1994 , 14, 95-8	4.6 8
3	Anti-neutrophil cytoplasmic antibody-associated paraneoplastic vasculitis. <i>Postgraduate Medical Journal</i> , 1994 , 70, 373-5	2 16

2	IgM antibodies to hepatitis C virus and haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 1994 , 9, 1211	4.3	5
1	Cardiac tamponade as presentation of systemic amyloidosis. <i>International Journal of Cardiology</i> , 1992 , 36, 107-8	3.2	19